BB Biotech AG (BION) - Net Assets
Based on the latest financial reports, BB Biotech AG (BION) has net assets worth CHF2.63 Billion CHF (≈ $3.33 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF2.64 Billion ≈ $3.34 Billion USD) and total liabilities (CHF7.86 Million ≈ $9.94 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BION tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF2.63 Billion |
| % of Total Assets | 99.7% |
| Annual Growth Rate | 1.65% |
| 5-Year Change | -15.51% |
| 10-Year Change | -7.47% |
| Growth Volatility | 25.61 |
BB Biotech AG - Net Assets Trend (2003–2025)
This chart illustrates how BB Biotech AG's net assets have evolved over time, based on quarterly financial data. See BION days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for BB Biotech AG (2003–2025)
The table below shows the annual net assets of BB Biotech AG from 2003 to 2025. For live valuation and market cap data, see BION market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CHF2.78 Billion ≈ $3.51 Billion |
+21.54% |
| 2024-12-31 | CHF2.29 Billion ≈ $2.89 Billion |
-1.59% |
| 2023-12-31 | CHF2.32 Billion ≈ $2.94 Billion |
-13.51% |
| 2022-12-31 | CHF2.69 Billion ≈ $3.40 Billion |
-18.33% |
| 2021-12-31 | CHF3.29 Billion ≈ $4.16 Billion |
-15.67% |
| 2020-12-31 | CHF3.90 Billion ≈ $4.93 Billion |
+14.95% |
| 2019-12-31 | CHF3.39 Billion ≈ $4.29 Billion |
+17.63% |
| 2018-12-31 | CHF2.88 Billion ≈ $3.65 Billion |
-18.49% |
| 2017-12-31 | CHF3.54 Billion ≈ $4.47 Billion |
+17.84% |
| 2016-12-31 | CHF3.00 Billion ≈ $3.80 Billion |
-24.51% |
| 2015-12-31 | CHF3.98 Billion ≈ $5.03 Billion |
+13.90% |
| 2014-12-31 | CHF3.49 Billion ≈ $4.42 Billion |
+64.83% |
| 2013-12-31 | CHF2.12 Billion ≈ $2.68 Billion |
+71.71% |
| 2012-12-31 | CHF1.23 Billion ≈ $1.56 Billion |
+23.19% |
| 2011-12-31 | CHF1.00 Billion ≈ $1.27 Billion |
-18.88% |
| 2010-12-31 | CHF1.23 Billion ≈ $1.56 Billion |
-18.56% |
| 2009-12-31 | CHF1.52 Billion ≈ $1.92 Billion |
+0.76% |
| 2008-12-31 | CHF1.50 Billion ≈ $1.90 Billion |
-14.85% |
| 2007-12-31 | CHF1.77 Billion ≈ $2.23 Billion |
-21.56% |
| 2006-12-31 | CHF2.25 Billion ≈ $2.85 Billion |
-1.18% |
| 2005-12-31 | CHF2.28 Billion ≈ $2.88 Billion |
+19.09% |
| 2004-12-31 | CHF1.91 Billion ≈ $2.42 Billion |
-1.28% |
| 2003-12-31 | CHF1.94 Billion ≈ $2.45 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BB Biotech AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 282.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CHF2.78 Billion | 99.90% |
| Common Stock | CHF11.08 Million | 0.40% |
| Total Equity | CHF2.78 Billion | 100.00% |
BB Biotech AG Competitors by Market Cap
The table below lists competitors of BB Biotech AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sinbon Electronics Co Ltd
TW:3023
|
$2.48 Billion |
|
Sanhe Tongfei Refrigeration Co. Ltd.
SHE:300990
|
$2.48 Billion |
|
TAV Havalimanlari Holding
IS:TAVHL
|
$2.48 Billion |
|
Wix.Com Ltd
NASDAQ:WIX
|
$2.48 Billion |
|
Artois Nom.
PA:ARTO
|
$2.48 Billion |
|
Banque Cantonale du Valais
SW:WKBN
|
$2.48 Billion |
|
Corporativo Fragua S.A.B. de C.V
MX:FRAGUAB
|
$2.48 Billion |
|
RBL Bank Limited
NSE:RBLBANK
|
$2.47 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BB Biotech AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,286,292,000 to 2,778,785,000, a change of 492,493,000 (21.5%).
- Net income of 578,133,000 contributed positively to equity growth.
- Dividend payments of 98,487,000 reduced retained earnings.
- Share repurchases of 5,037,000 reduced equity.
- New share issuances of 17,884,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF578.13 Million | +20.81% |
| Dividends Paid | CHF98.49 Million | -3.54% |
| Share Repurchases | CHF5.04 Million | -0.18% |
| Share Issuances | CHF17.88 Million | +0.64% |
| Total Change | CHF- | 21.54% |
Book Value vs Market Value Analysis
This analysis compares BB Biotech AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.88x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.96x to 0.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | CHF14.94 | CHF44.20 | x |
| 2004-12-31 | CHF15.26 | CHF44.20 | x |
| 2005-12-31 | CHF18.93 | CHF44.20 | x |
| 2006-12-31 | CHF18.91 | CHF44.20 | x |
| 2007-12-31 | CHF16.61 | CHF44.20 | x |
| 2008-12-31 | CHF17.00 | CHF44.20 | x |
| 2009-12-31 | CHF18.29 | CHF44.20 | x |
| 2010-12-31 | CHF15.64 | CHF44.20 | x |
| 2011-12-31 | CHF13.99 | CHF44.20 | x |
| 2012-12-31 | CHF21.06 | CHF44.20 | x |
| 2013-12-31 | CHF37.18 | CHF44.20 | x |
| 2014-12-31 | CHF61.65 | CHF44.20 | x |
| 2015-12-31 | CHF71.21 | CHF44.20 | x |
| 2016-12-31 | CHF54.34 | CHF44.20 | x |
| 2017-12-31 | CHF63.93 | CHF44.20 | x |
| 2018-12-31 | CHF52.07 | CHF44.20 | x |
| 2019-12-31 | CHF61.25 | CHF44.20 | x |
| 2020-12-31 | CHF70.18 | CHF44.20 | x |
| 2021-12-31 | CHF59.31 | CHF44.20 | x |
| 2022-12-31 | CHF48.52 | CHF44.20 | x |
| 2023-12-31 | CHF42.36 | CHF44.20 | x |
| 2024-12-31 | CHF41.70 | CHF44.20 | x |
| 2025-12-31 | CHF50.39 | CHF44.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BB Biotech AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.81%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 98.49%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.00x
- Recent ROE (20.81%) is above the historical average (6.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 9.25% | 92.67% | 0.10x | 1.02x | CHF-14.59 Million |
| 2004 | 10.59% | 94.90% | 0.11x | 1.00x | CHF11.31 Million |
| 2005 | 13.95% | 95.59% | 0.13x | 1.10x | CHF90.00 Million |
| 2006 | 13.20% | 93.50% | 0.12x | 1.13x | CHF72.11 Million |
| 2007 | -15.02% | -21081.10% | 0.00x | 1.18x | CHF-442.13 Million |
| 2008 | 3.01% | 64.39% | 0.04x | 1.08x | CHF-105.13 Million |
| 2009 | 2.42% | 67.46% | 0.04x | 1.00x | CHF-115.00 Million |
| 2010 | -11.85% | 0.00% | -0.10x | 1.12x | CHF-269.83 Million |
| 2011 | -6.50% | 0.00% | 0.00x | 1.15x | CHF-165.31 Million |
| 2012 | 29.81% | 97.62% | 0.27x | 1.11x | CHF244.43 Million |
| 2013 | 43.98% | 99.35% | 0.42x | 1.04x | CHF719.95 Million |
| 2014 | 42.09% | 99.58% | 0.42x | 1.01x | CHF1.12 Billion |
| 2015 | 16.41% | 99.03% | 0.16x | 1.04x | CHF255.00 Million |
| 2016 | -26.71% | 0.00% | -0.25x | 1.07x | CHF-1.10 Billion |
| 2017 | 19.43% | 99.20% | 0.19x | 1.03x | CHF333.64 Million |
| 2018 | -16.34% | 0.00% | -0.15x | 1.07x | CHF-759.79 Million |
| 2019 | 19.97% | 98.86% | 0.19x | 1.05x | CHF338.13 Million |
| 2020 | 17.78% | 98.85% | 0.18x | 1.02x | CHF302.42 Million |
| 2021 | -12.33% | 0.00% | -0.11x | 1.11x | CHF-733.16 Million |
| 2022 | -13.32% | 0.00% | -0.12x | 1.14x | CHF-626.43 Million |
| 2023 | -8.89% | -590305.71% | 0.00x | 1.14x | CHF-438.93 Million |
| 2024 | 3.32% | 67.99% | 0.05x | 1.05x | CHF-152.73 Million |
| 2025 | 20.81% | 98.49% | 0.21x | 1.00x | CHF300.25 Million |
Industry Comparison
This section compares BB Biotech AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $75,689,087
- Average return on equity (ROE) among peers: -68.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BB Biotech AG (BION) | CHF2.63 Billion | 9.25% | 0.00x | $2.48 Billion |
| Addex Therapeutics Ltd (ADXN) | $16.93 Million | -91.05% | 0.33x | $6.98 Million |
| Bachem Holding AG (BANB) | $365.36 Million | 11.28% | 0.36x | $5.20 Billion |
| Bioversys AG (BIOV) | $10.68 Million | -175.24% | 2.27x | $161.41 Million |
| Basilea Pharmaceutica AG (BSLN) | $-92.96 Million | 0.00% | 0.00x | $686.09 Million |
| Idorsia Ltd (IDIA) | $164.35 Million | -300.98% | 5.11x | $1.03 Billion |
| MINDMAZE THERAPEUTICS HOLDING SA (MMTX) | $38.34 Million | -25.84% | 0.34x | $46.13 Million |
| Molecular Partners AG (MOLN) | $135.79 Million | -13.71% | 0.36x | $145.86 Million |
| Newron Pharmaceuticals SpA (NWRN) | $-14.03 Million | 0.00% | 0.00x | $297.11 Million |
| Relief Therapeutics Holding AG (RLF) | $56.73 Million | -21.53% | 0.15x | $36.33 Million |
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domicile… Read more